Fierce Biotech May 7, 2024
Zenas BioPharma has bagged a $200 million series C, extending its cash runway another 18 months through a raft of key readouts for its lead monoclonal antibody obexelimab.
The new financing—Zenas’ second consecutive nine-digit haul—was led by SR One, New Enterprise Associates, Norwest Venture Partners and Delos Capital, according to Tuesday’s release. The primary use of the capital will be to advance mid- to late-stage trials of obexelimab, a monoclonal antibody being developed to treat a range of autoimmune diseases.
Lonnie Moulder, Zenas’ founder and CEO, said the decision to stay private was due in part to a tepid IPO scene when fundraising began.
“If you look at the public markets, and where they were just a number of months...
Today's Sponsors
Today's Sponsor